Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.
Monolix® software
pediatric oncology
pharmacokinetic population modeling
pharmacokinetics
sirolimus
therapeutic drug monitoring
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
30 Mar 2021
30 Mar 2021
Historique:
received:
01
03
2021
revised:
21
03
2021
accepted:
25
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM. In the RAPIRI phase I trial, the combination sirolimus + irinotecan was evaluated as a new treatment for refractory pediatric cancers. Blood sampling at first sirolimus intake (D1) and at steady state (D8), followed by LC/MS
Identifiants
pubmed: 33808416
pii: pharmaceutics13040470
doi: 10.3390/pharmaceutics13040470
pmc: PMC8067051
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 Apr 4;8(14):23851-23861
pubmed: 27793021
Clin Pharmacokinet. 2001;40(8):573-85
pubmed: 11523724
Clin Cancer Res. 2015 Apr 1;21(7):1558-65
pubmed: 25467181
Pediatr Blood Cancer. 2015 Mar;62(3):440-4
pubmed: 25446280
Br J Clin Pharmacol. 2015 Dec;80(6):1438-46
pubmed: 26256674
Nephrol Dial Transplant. 2006 Mar;21(3):562-8
pubmed: 16361278
Clin Cancer Res. 2009 Feb 15;15(4):1297-307
pubmed: 19190131
Clin Cancer Res. 2014 Jun 15;20(12):3133-45
pubmed: 24727322
Drug Metab Dispos. 2002 Jun;30(6):631-5
pubmed: 12019187
Pediatr Transplant. 2006 Dec;10(8):914-9
pubmed: 17096757
Cancers (Basel). 2020 Oct 20;12(10):
pubmed: 33092063
J Clin Pharmacol. 1997 May;37(5):405-15
pubmed: 9156373
Clin Pharmacokinet. 2005;44(8):769-86
pubmed: 16029064
Br J Clin Pharmacol. 2002 Jul;54(1):65-8
pubmed: 12100227
Expert Opin Investig Drugs. 2011 Dec;20(12):1685-705
pubmed: 22010859
Ther Drug Monit. 2013 Jun;35(3):332-7
pubmed: 23666574
Expert Rev Anticancer Ther. 2015 Mar;15(3):257-9
pubmed: 25586480
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34
pubmed: 15379381
Br J Clin Pharmacol. 2006 Oct;62(4):420-34
pubmed: 16995863
Lancet Oncol. 2017 Jul;18(7):946-957
pubmed: 28549783
Pediatr Blood Cancer. 2014 Jan;61(1):128-33
pubmed: 23956145
Br J Clin Pharmacol. 2005 Nov;60(5):566-9
pubmed: 16236048
Laryngoscope. 2011 May;121(5):978-82
pubmed: 21520111
Pediatr Blood Cancer. 2020 Apr;67(4):e28134
pubmed: 31876107
Br J Cancer. 2013 Mar 5;108(4):826-30
pubmed: 23412108
Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28205374
J Med Biochem. 2019 May 11;38(3):323-331
pubmed: 31156343
Front Pharmacol. 2020 Jun 30;11:973
pubmed: 32695000
Biol Blood Marrow Transplant. 2013 Apr;19(4):569-75
pubmed: 23266742
Transl Androl Urol. 2020 Apr;9(2):673-683
pubmed: 32420174
Clin Cancer Res. 2004 Oct 15;10(20):7031-42
pubmed: 15501983
J Clin Pharmacol. 1996 Dec;36(12):1100-6
pubmed: 9013365
Pharm Res. 2003 Jun;20(6):910-7
pubmed: 12817897
Pediatr Blood Cancer. 2008 Apr;50(4):799-805
pubmed: 17635004
Mol Cancer Ther. 2010 Jan;9(1):101-12
pubmed: 20053767
Drug Metab Dispos. 2002 Sep;30(9):1029-34
pubmed: 12167569
Br J Clin Pharmacol. 2017 May;83(5):1097-1107
pubmed: 28000286
Pediatr Blood Cancer. 2014 May;61(5):833-9
pubmed: 24249672
Diabetes Res Clin Pract. 2015 Nov;110(2):101-8
pubmed: 26421362
Oncotarget. 2017 Mar 23;8(42):71597-71617
pubmed: 29069732